Biotechnology Company Successfully Completes Pre-IND Meeting With FDA For OUD
For Incannex, this teleconference was a platform to engage with various divisions of the FDA.
Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward pertains to the development of CannQuit-O, a pioneering treatment designed for Opioid Use Disorder (OUD), signifying a potential breakthrough in the battle against one of the most pressing public health crises. $Incannex Healthcare (IXHL.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
